Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Eye sequelae following external irradiation

M Hempel1, W Hinkelbein

  • 1Department of Radiotherapy, University Hospital, Freiburg, Fed. Rep. of Germany.

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Search for heavy resonances that decay into a vector boson and a Higgs boson in hadronic final states at <math> </math> <math></math>.

The European physical journal. C, Particles and fields·2020
Same author

Search for physics beyond the standard model in events with two leptons of same sign, missing transverse momentum, and jets in proton-proton collisions at <math> </math>.

The European physical journal. C, Particles and fields·2020
Same author

Search for new phenomena with the <math></math> variable in the all-hadronic final state produced in proton-proton collisions at <math> </math> <math></math>.

The European physical journal. C, Particles and fields·2020
Same author

Measurement of the triple-differential dijet cross section in proton-proton collisions at <math> </math> and constraints on parton distribution functions.

The European physical journal. C, Particles and fields·2020
Same author

Measurements of the associated production of a Z boson and b jets in pp collisions at <math> </math>.

The European physical journal. C, Particles and fields·2020
Same author

Search for dark matter produced in association with heavy-flavor quark pairs in proton-proton collisions at <math> </math>.

The European physical journal. C, Particles and fields·2020

Radiotherapy can cause early eye issues like conjunctivitis and corneal damage, and late complications such as cataracts, retinopathy, and optic neuropathy. Reducing daily radiation fractions to 1.7-1.8 Gy may minimize these ocular side effects.

Area of Science:

  • Ophthalmology
  • Radiation Oncology
  • Oncology

Background:

  • Radiotherapy is crucial for treating head and neck cancers, but ocular structures are susceptible to radiation-induced damage.
  • Early and late ocular complications can significantly impact patient quality of life and vision.
  • Understanding radiation tolerance of ocular tissues is vital for treatment planning.

Purpose of the Study:

  • To review the spectrum of early and late ocular complications following radiotherapy.
  • To discuss the dose-response relationship and latency periods for various ocular toxicities.
  • To highlight the need for prospective trials and suggest strategies for minimizing ocular damage.

Main Methods:

  • Literature review of ocular complications from radiotherapy.

Related Experiment Videos

  • Analysis of dose-response relationships and latency periods for radiation-induced ocular toxicities.
  • Discussion of risk factors and management strategies.

    • Main Results:

    • Early reactions include transient conjunctivitis and corneal damage, with higher doses risking ulceration and eye loss.
    • Cataract formation is the most frequent late reaction, with a low tolerance dose (approx. 5 Gy).
    • Severe late complications include retinopathy and optic neuropathy, potentially causing significant visual loss and blindness at doses of 50-70 Gy.

    Conclusions:

    • Ocular complications from radiotherapy range from mild early effects to severe late-onset visual impairment.
    • Dose reduction, particularly to 1.7-1.8 Gy per fraction, is recommended to minimize ocular toxicity.
    • Further prospective studies are needed to accurately assess risks for specific tumor sites and optimize treatment protocols.